Zomedica Corp. (ZOM)
USD 0.1
(-0.21%)
USD 0.1
(-0.21%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 13.18 Million USD | 7.87% |
| 2023 | 12.21 Million USD | 28.42% |
| 2022 | 9.51 Million USD | -36.9% |
| 2021 | 15.07 Million USD | 622.3% |
| 2020 | 2.08 Million USD | -12.16% |
| 2019 | 2.37 Million USD | 186.76% |
| 2018 | 828.73 Thousand USD | 11.82% |
| 2017 | 741.15 Thousand USD | 406.64% |
| 2016 | 146.28 Thousand USD | 3621.0% |
| 2015 | 3931.45 USD | -23.77% |
| 2014 | 5157.01 USD | 427.95% |
| 2013 | 976.80 USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 FY | 13.18 Million USD | 7.87% |
| 2024 Q1 | 16.54 Million USD | 35.37% |
| 2024 Q3 | 14.16 Million USD | -7.39% |
| 2024 Q4 | 13.18 Million USD | -6.97% |
| 2024 Q2 | 15.29 Million USD | -7.5% |
| 2023 Q4 | 12.21 Million USD | -9.62% |
| 2023 Q1 | 8.94 Million USD | -5.94% |
| 2023 Q3 | 13.51 Million USD | 46.01% |
| 2023 FY | 12.21 Million USD | 28.42% |
| 2023 Q2 | 9.25 Million USD | 3.45% |
| 2022 Q1 | 2.94 Million USD | -80.5% |
| 2022 Q2 | 4.28 Million USD | 45.68% |
| 2022 Q3 | 5.94 Million USD | 38.69% |
| 2022 Q4 | 9.51 Million USD | 60.12% |
| 2022 FY | 9.51 Million USD | -36.9% |
| 2021 Q3 | 3.22 Million USD | 1.32% |
| 2021 Q2 | 3.18 Million USD | 3.24% |
| 2021 Q4 | 15.07 Million USD | 367.6% |
| 2021 FY | 15.07 Million USD | 622.3% |
| 2021 Q1 | 3.08 Million USD | 47.68% |
| 2020 Q1 | 7.77 Million USD | 227.11% |
| 2020 Q4 | 2.08 Million USD | 32.33% |
| 2020 FY | 2.08 Million USD | -12.16% |
| 2020 Q2 | 1.79 Million USD | -76.89% |
| 2020 Q3 | 1.57 Million USD | -12.2% |
| 2019 Q4 | 2.37 Million USD | 85.61% |
| 2019 Q3 | 1.28 Million USD | -23.96% |
| 2019 Q1 | 1.26 Million USD | 52.8% |
| 2019 Q2 | 1.68 Million USD | 32.97% |
| 2019 FY | 2.37 Million USD | 186.76% |
| 2018 Q2 | 511.4 Thousand USD | -51.05% |
| 2018 Q4 | 828.73 Thousand USD | 116.21% |
| 2018 Q3 | 383.29 Thousand USD | -25.05% |
| 2018 FY | 828.73 Thousand USD | 11.82% |
| 2018 Q1 | 1.04 Million USD | 40.96% |
| 2017 Q1 | 6357.42 USD | -68.33% |
| 2017 FY | 741.15 Thousand USD | 406.64% |
| 2017 Q4 | 741.15 Thousand USD | 55.83% |
| 2017 Q3 | 475.63 Thousand USD | 52.01% |
| 2017 Q2 | 312.89 Thousand USD | 4821.76% |
| 2016 Q1 | 3923.53 USD | 1516.61% |
| 2016 FY | 146.28 Thousand USD | 3621.0% |
| 2016 Q4 | 20.07 Thousand USD | 17390.63% |
| 2016 Q3 | 114.79 USD | -97.91% |
| 2016 Q2 | 5493.29 USD | 40.01% |
| 2015 FY | 3931.45 USD | -23.77% |
| 2015 Q1 | 5157.01 USD | 19.78% |
| 2015 Q4 | 242.70 USD | 4.31% |
| 2015 Q2 | 2437.61 USD | -52.73% |
| 2015 Q3 | 232.68 USD | -90.45% |
| 2014 Q3 | 948.59 USD | -2.23% |
| 2014 FY | 5157.01 USD | 427.95% |
| 2014 Q4 | 4305.44 USD | 353.88% |
| 2014 Q2 | 970.23 USD | 0.0% |
| 2013 FY | 976.80 USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| China Pharma Holdings, Inc. | 9.01 Million USD | -46.208% |
| cbdMD, Inc. | 7.16 Million USD | -83.975% |
| cbdMD, Inc. | 7.16 Million USD | -83.975% |